Editas Medicine, Inc. - Common Stock — Bilan (NASDAQ:EDIT)

Afficher le graphique complet Full chart

Financials

Total de l'actif 572.6 M677.48 M514.32 M499.15 M341.59 M186.53 M Total du passif 179.02 M123.84 M153.64 M150.06 M207.31 M159.25 M Total des capitaux propres 393.59 M553.64 M360.68 M349.1 M134.27 M27.29 M Total du passif et des capitaux propres 572.6 M677.48 M514.32 M499.15 M341.59 M186.53 M Dette totale ————52.43 M53.6 M Dette nette ————52.43 M53.6 M

Editas Medicine, Inc. - Common Stock

Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

EDIT

Financials

Editas Medicine, Inc. - Common Stock

Nouvelles

Editas Medicine: Resetting Pipeline Just To Be Second To Market Again (NASDAQ:EDIT)

L’action Editas Medicine chute après l’annonce d’une offre d’actions

Editas Medicine lance une offre publique d’actions et de bons de souscription

Editas présente des données précliniques pour son traitement d’édition génique

Editas Medicine présente des données précliniques sur la thérapie EDIT-401

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Company News for May 6, 2026

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas Medicine présentera des données précliniques sur la thérapie EDIT-401

Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?